1. EU-SCCS (2011) Opinion on N-Methyl-2-pyrrolidone. Scientific Committee on Consumer Safety (Ed). European Commission Health & Consumers, Directorate D: Health Systems and Products, Unit D3– Risk Assessment. European Union, Brussels, Belgium. http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_050.pdf
2. ECHA (2011) 1-Methyl-2-pyrrolidone. Inclusion of Substances of Very High Concern in the Candidate List (Decision of the European Chemicals Agency). DOC: ED/31/2011. European Chemicals Agency, Helsinki, Finland. http://echa.europa.eu/documents/10162/b6b72fb4-fff0-43dd-be25-963428f8f726
3. WHO (2001) N-Methyl-2-pyrrolidone. Concise International Chemical Assessment Document 35. WHO Press, Geneva
4. Jouyban A, Fakhree MA, Shayanfar A (2010) Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J Pharm Pharm Sci 13:524–535
5. Boenisch U, Bohme A, Kohajda T et al (2012) Volatile organic compounds enhance allergic airway inflammation in an experimental mouse model. PLoS One 7:e39817